Actelion Aims To Expand Opsumit Uses, Build Diversified Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Actelion says its robust financial performance in 2013, a strong U.S. launch for its new PAH drug Opsumit and a growing pipeline that includes more than 15 preclinical projects has positioned it well for further product diversification in 2014 and beyond.